Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1444-1451

  Rouan, Marie Claude ^a   Lounis, Nacer ^a   Gevers, Tom ^a   Dillen, Lieve ^b   Gilissen, Ron ^b   Raoof, Araz ^a   Andries, Koen ^b  

^a TIBOTEC BVBA   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DRUG METABOLITE; N DESMETHYL TMC 207; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL LOAD; BACTERIUM CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; FEMALE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; ATP SYNTHETASE COMPLEXES; BACTERIAL PROTEINS; BIOTRANSFORMATION; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HALF-LIFE; HUMANS; LUNG; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS, PULMONARY;

EID: 84857157134     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00720-11     Document Type: Article

References (21)

1. Ahmad Z, et al. 2011. PA-824 exhibits time-dependent activity in a murine 1 model of tuberculosis. Antimicrob. Agents Chemother. 55:239-245.
2. Andries K, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. (Pubitemid 40116230)
3. Davies GR, Nuermberger EL. 2008. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis. 88:S65-S74.
4. Dhillon J, Andries K, Phillips PPJ, Mitchison DA. 2010. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 90:301-305.
5. Diacon AH, et al. 2009. The diarylquinoline TMC207 in multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
6. Huitric E, Verhasselt P, Andries K, Hoffner S. 2007. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 51:4202-4204. (Pubitemid 350057830)
7. Ibrahim M, et al. 2007. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 51:1011-1015. (Pubitemid 46355288)
8. Jayaram R, et al. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124. (Pubitemid 36753560)
9. Jayaram R, et al. 2004. Isoniazid Pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 48:2951-2957. (Pubitemid 38989160)
10. Koul A, et al. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3:323-324. (Pubitemid 46789271)
11. Lounis N, et al. 2010. R207910 (TMC207): a new antibiotic for the treatment of tuberculosis. Med. Mal. Infect. 40:383-390.
12. Lounis N, et al. 2006. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50:3543-3547. (Pubitemid 44684863)
13. Mesens N, et al. 2010. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol. in vitro 24:1417-1425.
14. Mouton JW, et al. 2008. Tissue concentrations: do we ever learn? J. Antimicrob. Chemother. 61:235-237.
15. Pasipanodya J, Gumbo T. 2011. An oracle: antituberculosis pharmacokinetics- pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 55:24-34.
16. Reasor MJ, Kacew S. 2001. Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. (Maywood) 226:825-830. (Pubitemid 34053231)
17. Shandil RK, et al. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582. (Pubitemid 46185275)
18. Veziris N, et al. 2009. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 179:75-79.
19. World Health Organization. 2009. Global tuberculosis control 2009: epidemiology, strategy, financing. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report /2009/pdf/full-report.pdf.
20. Yajko DM, Kirihara J, Sanders C, Nassos P, Hadley WK. 1988. Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob. Agents Chemother. 32:1392-1395.
21. Yew WW, Cynamon M, Zhang Y. 2011. Emerging drugs for the treatment of tuberculosis. Expert Opin. Emerg. Drugs 16:1-21.